Recognizing the interaction of B cell clonogenic vp17s with PAR-1, CXCR1, and CXCR2 as key events in sustaining lymphoma growth and dissemination prompts us to study whether the AT20-KLH therapeutic vaccine may represent a promising strategy for fighting AIDS-related lymphomas. This evidence concerns the gene CXCR2 and lymphoma.